openPR Logo
Press release

Collaborations and Alliances Increasing as the Market for Prefilled Syringes Matures

11-28-2016 10:18 AM CET | Health & Medicine

Press release from: Greystone Research Associates

(Amherst, NH) – The administration of therapeutic drugs via injection is an indispensable delivery method for numerous drugs critical to patient health and well-being. Now this segment is evolving in response to changing market conditions, increased competition from generics, consolidation within supply chains, and healthcare administration initiatives.

The injectable drug ecosystem consists of several segments that include syringe component suppliers, syringe manufacturers, and contract filling companies. Within these layers are specialty service providers that include, among others, formulation technology developers, device designers, and physical properties testing. For small-to–mid size companies, many of these functions are outsourced. Because of the complexity of this ecosystem relative to vial packaging, the decision to develop an injectable for administration with a prefilled device is being made earlier in the drug development cycle, as product managers and marketers understand the need to take full advantage of combination product opportunities.

There are less than a dozen important prefilled syringe manufacturers worldwide. These companies have significant operations and investment in materials technology and injection device fabrication and commercialization. While several major suppliers have manufacturing sites on more than one continent, even those that are based in one regional or geographic area have extensive facilities designed to handle most or all or most of the design/development/manufacturing cycle requirements associated with syringe creation, production and commercialization.

While prefillable syringe manufacturers continue to improve and refine their products, from a materials technology standpoint the most dynamic developments are occurring in the evolution of PFS constructed of plastic rather than glass. To date, plastic PFS have made significant inroads in EMS injectables, a segment dominated by plastic PFS. Now, as materials technology continues to advance, market sector participants are targeting mainstream therapeutic drugs.

As the market matures, prefillable syringe and injector suppliers are attempting to keep pace with the changing injectables landscape, adding capacity, integrating operations in-house for capabilities that are trending up, and shedding business units and in some cases branded devices to stay current with what is perceived to be the latest injectable drug market direction .

Major therapeutic markets for self-administered subcutaneous injectables include autoimmune diseases, hormone replacement, metabolic diseases such as diabetes and osteoporosis, and blood thinners. And while oncology drugs continue to be developed for infusion in a healthcare setting, the approval of Roche’s Herceptin, an antibody indicated for treating HER2-positive breast cancer, as a subcutaneous formulation (Herceptin SC) in Europe last year is a glimpse into the future. Herceptin SC is enabled by recombinant technology supplied by Halozyme.

Detailed analysis of the global prefilled syringe market is contained in a new and comprehensive report. Prefilled Syringes in 2017 and Beyond: the Products, the Markets the Collaborations examines the prefilled syringe market as it continues to mature.

More information is available at

Source: Greystone Research Associates

About Greystone

Greystone Research Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.


Mark Smith
Greystone Research Associates
98 Route 101A
Amherst, NH 03031 USA
Voice: 603-595-4340
Fax: 603-218-7020

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Collaborations and Alliances Increasing as the Market for Prefilled Syringes Matures here

News-ID: 387622 • Views: 240

More Releases from Greystone Research Associates

Seeking to Capitalize on New Device Technology Drug Companies are Reformulating …
(Amherst, NH) – As the pace of competition increases within the pharmaceutical and biotech industries, the concept of life cycle management is becoming a key component of drug product management. Much of the recent emphasis in this area has centered on efforts to extend patent rights protection. While reformulation has been and is an important approach, efforts to prolong IP benefits have only recently involved IV-to-SC drug re-engineering. This migration
Antibacterial Treatments that don’t Rely on Antibiotics Winding their way thro …
(Amherst, NH) – As bacteria grow resistant to conventional antibiotics, alternatives are being investigated, including antibodies, probiotics, bacteriophages, and antimicrobial peptides. The quest to replace the current generation of antibiotics is complicated by the methods that bacteria have acquired to evade attempts to destroy them – methods often referred to a virulence factors. A microorganism can possess a wide array of virulence factors. They may only express these virulence factors when
3D Printing Positioned to Address Issues that have Prevented Wide Adoption of Mi …
(Amherst, NH) – The promise of commercial microneedle drug delivery has been on the horizon for more than a decade. Like other compelling medical device innovations such as noninvasive glucose monitoring, the potential of the technology has yet to be realized due to the inability to solve the issues of reliable product performance from unit to unit and across a wide user population. To fully address the unmet need these technologies
Analysis of the Oncology Drug Pipeline Reveals Evolving Therapy Correlations and …
(Amherst, NH) – The almost two thousand active oncology clinical trials paint a picture of an evolving therapeutic sector that has established players moving quickly to realize the expanded benefits of recent treatment protocols. A dozen targeted treatments, using novel pathways and signaling, have achieved results that represent a new era in oncology and antineoplastic therapeutics. There approaches have attracted a growing number of drug developers anxious to profit from

All 5 Releases

More Releases for PFS

PFS Rubber Stopper 2019 Global Market Outlook, Research, Trends and Forecast to …
PFS Rubber Stopper Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. Get Exclusive FREE Sample Copy Of this Report @ UpMarketResearch offers a latest published report on “Global PFS Rubber Stopper Market Analysis and Forecast 2019 - 2025” delivering key insights and providing a competitive
Meet top PFS experts, network with 100+ pharma and biotech industry leaders next …
SMi Group reports: Last call for registrations to Pre-Filled Syringes East Coast conference SMi’s global portfolio of events on Pre-Filled Syringes secured an audience of over 300 senior drug delivery and medical device experts over the last year. Next week, April 8 – 9, in Boston, will be held the 6th annual Pre-Filled Syringes East Coast conference and exhibition where industry leaders from pharmaceutical, biotech and device manufacturing, meet to get
PFS Development – challenges and solutions, Pre-Filled Syringes East Coast is …
Despite lucrative opportunities in the PFS industry, there are a few ongoing challenges that the key-leaders battle to overcome, including human factor considerations, new laws, user interface considerations and patient safety. SMi’s Pre-Filled Syringes East Coast Conference (8 - 9 April, Boston, US) is a place to debate these issues, engage with experts and determine strategy. One of the main features of the event will be what the future of
Hear from PFS industry leaders from big pharma, government bodies & top manufact …
SMi Reports: 11th Annual Conference and Exhibition on Pre-Filled Syringes & Injectable Drug Devices will take place in just over a months’ time on the 16th-17th January 2019 in London. This premium event will feature over 100 selected senior pre-filled syringes experts from leading PFS markets, including Austria, Belgium, Finland, France, Germany, Japan, Switzerland, UK, USA and many other countries. Event attendees will gather to discuss solutions to accelerate PFS
Parenteral drug delivery: optimizing and developing novel methods in PFS industr …
Pre-Filled Syringes West Coast: SMi Groups latest instalment in the industry renowned Pre-Filled Syringes global event series welcoming industry leaders this June in San Diego, USA The conference programme is tailored around industry needs and is packed with market-led case studies offering progressive insight into parenteral drug delivery. Pre-Filled Syringes West Coast show is taking place on June 4 – 5 in San Diego, CA with an additional day (June 6
Future of PFS injection devices from cross-industry expertise perspectives – d …
With just over a month away, SMi's Pre-Filled Syringes West Coast show (June 4 - 5, San Diego, CA) is set to beat the record in attendee interest. Set to attend the event are: AbbVie, Allergan, Amgen, Antares Pharma, Aptar Pharma, Baxter Healthcare, Boehringer Ingelheim, Credence MedSystems, Ferring Pharmaceuticals, Genentech, Gilead Science, Glenmark Pharmaceuticals, Ionis Pharmaceuticals, Merck & Co., Novo Nordisk, Pfizer, Regeneron, Shire, Xeris Pharmaceuticals, amongst others. Visit Pre-Filled